Timothy Rolph - Jan 27, 2025 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Jan 27, 2025
Transactions value $
-$1,102,016
Form type
4
Date filed
1/29/2025, 08:43 PM
Previous filing
Jan 10, 2025
Next filing
Feb 7, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $298K +15K +8.8% $19.87 185K Jan 27, 2025 Direct F1
transaction AKRO Common Stock Options Exercise $343K +16.3K +8.78% $21.10 201K Jan 27, 2025 Direct F1
transaction AKRO Common Stock Sale -$756K -13.8K -6.86% $54.76 188K Jan 27, 2025 Direct F1, F2
transaction AKRO Common Stock Sale -$281K -5.06K -2.7% $55.62 183K Jan 27, 2025 Direct F1, F3
transaction AKRO Common Stock Sale -$705K -12.4K -6.78% $56.97 170K Jan 27, 2025 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -15K -11.1% $0.00 120K Jan 27, 2025 Common Stock 15K $19.87 Direct F1, F5
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -16.3K -19.72% $0.00 66.2K Jan 27, 2025 Common Stock 16.3K $21.10 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2024, previously adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.19 to $55.18, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $55.35 to $56.15, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $56.61 to $57.03, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5 This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023.
F6 This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2021.